A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)

Phase 3 Active not recruiting 311 enrolled Janssen Research & Development, LLC

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque psoriasis affecting special areas (scalp, genital, and/or palms of the hands and the soles of the feet).

Timeline

Start: 2023-10-12
Primary completion: 2024-06-19
Completion: 2027-02-17

Outcome

Met primary endpoint

registry Arm 1: Placebo vs Arm 2: JNJ-77242113 200 mg; p <0.001; Treatment difference 51.1 (95% CI 42.1 to 58.8) NCT06095102 ↗

release “ICONIC-TOTAL study showed once daily icotrokinra met the primary endpoint of IGA of 0/1 at week 16” jnj.com ↗

Publications

Gooderham M, Lain E, Bissonnette R, Huang YH, Lynde CW, Hoffmann M, Song EJ, Weirich O, Ceitlin RHG, Rubens JH, DeLozier AM, Ota T, Hsu MC, Li S, DeKlotz CMC, Nunes F, Warren RB. Targeted Oral Peptide Icotrokinra for Psoriasis Involving High-Impact Sites. NEJM Evid. 2025 Dec;4(12):EVIDoa2500155. doi: 10.1056/EVIDoa2500155. Epub 2025 Nov 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Icotrokinra	Peptide	200 mg	Oral